Does tirzepatide cause hair loss? What the 2026 data shows

The new numbers on GLP-1 hair loss risk

Hair loss complaints have circulated on GLP-1 forums almost since Ozempic became a household name. The question has always been: is this a real signal, how common is it, and which drug is worse?

Until 2026, the answer was mostly anecdote and adverse event reports. A cohort study using the TriNetX federated research database changed that. Published in the Journal of the American Academy of Dermatology, it compared adults newly starting semaglutide or tirzepatide against those starting metformin, a common diabetes medication with no known hair loss association, and followed them for new-onset nonscarring hair loss.

The results: tirzepatide users had a relative risk of 1.68. Semaglutide users came in at 1.43. Both are statistically significant signals. Neither means that most users lose hair. A relative risk of 1.68 means roughly 68% higher risk than the metformin comparison group, not that 68% of tirzepatide users experience noticeable shedding.

A 2026 systematic review published in SAGE Open Medicine, pooling earlier pharmacovigilance and cohort data, confirmed the pattern: among all GLP-1 receptor agonists, semaglutide and tirzepatide showed the highest reporting rates and the most consistent signals across studies. The Wiley systematic review in the International Journal of Dermatology, also published in 2026, reached the same conclusion.

What type of hair loss

This distinction matters clinically. Not all hair loss is permanent or follicle-damaging.

Telogen effluvium is the pattern most consistently linked to GLP-1 drugs. It shows up as diffuse thinning across the scalp rather than discrete patches or a receding hairline. You notice more hair in the shower, on the brush, or on the pillow. It can be striking in volume. It is not a sign that follicles are dying.

What is actually happening: a larger-than-normal fraction of hair follicles have shifted from the anagen (growth) phase into the telogen (resting) phase. A few months later, those hairs shed simultaneously. The follicles themselves are intact. When the underlying trigger resolves, they cycle back into growth.

Androgenetic alopecia (pattern baldness) was also reported in the literature. But the 2026 Wiley systematic review found telogen effluvium to be the dominant subtype, particularly for tirzepatide. Androgenetic alopecia progresses differently, does not self-resolve, and has different treatments. Anyone experiencing patchy or receding-pattern loss should see a dermatologist to distinguish the two.

Why the drug triggers it

The 2026 SAGE systematic review is direct about mechanism: the association is most consistent with weight-loss-induced telogen effluvium rather than direct follicular toxicity. The drug does not attack hair follicles. It creates conditions for a well-documented physiological response.

The same pattern appears after bariatric surgery, after very-low-calorie diets, and after serious illness. Hair follicle tissue is metabolically expensive and non-essential for survival. During energy scarcity, the body deprioritizes it. The follicle biology is consistent across all these contexts.

There is a plausible secondary mechanism. GLP-1 receptors are expressed in skin and hair follicle tissue, so some direct follicular effect is biologically possible. But the dose-dependence data pushes against that being the primary driver.

The dose-dependence clue

A 2026 systematic review found that semaglutide-linked hair loss followed a clear dose-response pattern. Doses below 2mg per week were rarely implicated. Higher doses, which produce more aggressive weight loss, appeared more frequently in the hair loss literature.

That is what you would expect if weight-loss induction is the mechanism. A drug producing 10% weight loss in 24 weeks is a different physiological stress than one producing 20% in the same window. Tirzepatide generates more total weight loss than semaglutide on average, and it shows a higher hair loss relative risk. The pattern fits. See the comparison of the two drugs on efficacy and side effects for the full picture.

This also connects to the muscle loss data from GLP-1 trials. Rapid weight loss stresses multiple tissue types at once. Hair and muscle are both metabolically demanding, and both show stress responses during aggressive caloric restriction. The underlying mechanism is shared.

Who is most likely to notice it

Women are disproportionately represented in hair loss reports across every GLP-1 study. This may reflect lower baseline hair density on average, greater hormonal sensitivity in follicles, or reporting patterns. It may also simply reflect that women are more likely to notice and report hair changes.

People losing more than 10% of body weight over a short period face higher risk than those on slower trajectories. Rapid escalation through dose phases compresses the weight-loss stress into a shorter window.

Baseline nutritional status is a significant modifier. Iron deficiency, low ferritin, zinc deficiency, and vitamin D deficiency each independently amplify telogen effluvium. GLP-1 drugs suppress appetite substantially. Patients eating 30-50% less than usual can develop micronutrient gaps that compound the shedding already triggered by weight loss itself.

What actually helps

Three interventions have genuine evidence behind them for this context.

Protein is the most important. The target during caloric restriction for someone concerned about tissue loss, for both hair and muscle, is 1.2-1.6g of protein per kilogram of body weight daily. That is harder to hit than it sounds when appetite suppression is significant. Tracking protein specifically during the dose-escalation phase is useful. The peptide and protein stack guidance for GLP-1 users covers this in more detail.

Labs matter more than supplements. Getting iron, ferritin, zinc, and vitamin D checked before attributing everything to the drug gives you actionable information. Correcting a real deficiency does more than stacking supplements preventively. A dermatologist can order these and interpret the results in context.

Time is the third intervention. Telogen effluvium is self-limiting. Once body weight stabilizes and nutritional intake normalizes, follicles cycle back into the growth phase. Most cases resolve without treatment in 6-9 months. Shedding that persists past 9 months or presents as patches rather than diffuse thinning should be evaluated for other causes.

Biotin comes up constantly in hair loss discussions and GLP-1 forums. It helps when biotin deficiency is the problem, which is uncommon in people eating a varied diet. There is no evidence that supplemental biotin reduces telogen effluvium in people who are not deficient. It is not harmful, but it is probably not the answer.

Putting this in context

The GLP-1 outcomes data over the past three years has been striking. SELECT showed semaglutide cutting cardiovascular events by 20% in people without diabetes. FLOW showed a 24% reduction in kidney failure risk. The SOUL trial cut major cardiac events by 14% in high-risk type 2 diabetes patients. These are meaningful effects on serious outcomes.

Hair loss is real, it affects some patients meaningfully, and it deserves a straight answer, not reassurance. But it is also mostly temporary and manageable. Telogen effluvium does not mean permanent follicle loss. The question people are actually asking is: will it grow back? The honest answer, for most people, is yes.

For anyone who qualifies for a GLP-1 program and is weighing this risk, the signal at RR 1.43-1.68 is worth knowing. It is not a reason to avoid effective treatment for most people. Adequate protein intake and a labs check before or shortly after starting can reduce severity if shedding does occur.